[Skip to Navigation]
Editor's Correspondence
Nov 26, 2012

Freedom to Innovate: The Perils of Centralized Medical Research

Author Affiliations

Author Affiliations: Leonard D. Schaeffer Center for Health Policy and Economics (Drs Huesch and Lakdawalla), Sol Price School of Public Policy (Drs Huesch and Lakdawalla) and School of Pharmacy (Dr Lakdawalla), University of Southern California, Los Angeles.

Arch Intern Med. 2012;172(21):1692-1693. doi:10.1001/2013.jamainternmed.53

Prasad and colleagues1 present a viewpoint on the evolution of medical practices, with a striking claim and a problematic recommendation. They claim that there is “no incentive for companies to test scientific questions, which may only diminish market demand.”1(p957) Their proffered solution is that “trial funding should move away from industry-sponsored studies and toward a model where funds are pooled into a central and impartial agency that decides what trials to administer.”1(p957)

Add or change institution